Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CACNA1B known ✓ | Q00975 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9403565 | 0.95 | ALDH1A1 (0.31) | ALDH1A1HRH3 | |
| Hydrochloric Acid SCHEMBL3521843 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL5325738 | 0.95 | ALDH1A1 (0.36) | ALDH1A1HRH3MGLLCYP2C9HPGD | |
| Hydrochloric Acid SCHEMBL7930062 | 0.95 | ALDH1A1 (0.36) | ALDH1A1HRH3MGLLCYP2C9HPGD | |
| Hydrochloric Acid SCHEMBL10651080 | 0.95 | ALDH1A1 (0.36) | ALDH1A1HRH3MGLLCYP2C9HPGD | |
| Hydrochloric Acid SCHEMBL844 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL5047658 | 0.95 | ALDH1A1 (0.36) | ALDH1A1HRH3MGLLCYP2C9HPGD | |
| Hydrochloric Acid SCHEMBL8812637 | 0.95 | ALDH1A1 (0.36) | ALDH1A1HRH3MGLLCYP2C9HPGD | |
| SCHEMBL10619765 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL11782028 | 0.95 | ALDH1A1 (0.36) | ALDH1A1HRH3MGLLCYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0892774-A4 | PYRONIN ANTIBACTERIALS, PROCESS AND NOVEL INTERMEDIATES THERETO | ANADYS PHARMACEUTICALS INC (US) | 2001-10-04 | — | — | EP | claimed |
| US-6090953-A | PREPARING A MYXOPYRONIN | SCRIPTGEN PHARMACEUTICALS, INC. (US) | 2000-07-18 | — | — | US | claimed |
| EP-0892774-A2 | PYRONIN ANTIBACTERIALS, PROCESS AND NOVEL INTERMEDIATES THERETO | SCRIPTGEN PHARMACEUTICALS, INC. (US) | 1999-01-27 | — | — | EP | claimed |
| WO-1997034569-A2 | PYRONIN ANTIBACTERIALS, PROCESS AND INTERMEDIATES | SCRIPTGEN PHARMACEUTICALS, INC. (US) | 1997-09-25 | — | — | WO | claimed |
| CN-105111103-B | The preparation method of salicylonitrile and its derivative | 重庆紫光化工股份有限公司 | 2018-04-24 | — | — | CN | disclosed |
| CN-105111103-A | Method for preparing cyanophenol and derivative thereof | CHONGQING UNISPLENDOUR CHEM CO | 2015-12-02 | — | — | CN | disclosed |
| EP-0892774-A4 | PYRONIN ANTIBACTERIALS, PROCESS AND NOVEL INTERMEDIATES THERETO | ANADYS PHARMACEUTICALS INC (US) | 2001-10-04 | — | — | EP | disclosed |
| US-6239291-B1 | Pyronin antibacterials, process and novel intermediates thereto | SCRIPTGEN PHARMACEUTICALS, INC. | 2001-05-29 | — | — | US | disclosed |
| US-6228882-B1 | MYXOPYRONINS AND CORALLOPYRONINS; RNA POLYMERASE INHIBITORS; SAPONIFICATION, ACIDIFICATION, AZIDING, ACYLATION | ANADYS PHARMACEUTICALS, INC. | 2001-05-08 | — | — | US | disclosed |
| US-6191288-B1 | Pyronin antibacterials, process and novel intermediates thereto | ANADYS PHARMACEUTICALS, INC. | 2001-02-20 | — | — | US | disclosed |
| US-6184393-B1 | MYXOPYRONINS AND CORALLOPYRONINS AS FURAN AND PYRAN- AND SMALL LACTONE-ANTIBIOTICS; INHIBITORS OF RNA POLYMERASE (RNAP) HAVING SELECTIVITY FOR HUMAN RNAP, CELL PENETRATION AND POTENCY AGAINST RIFAMPICIN-RESISTANT STAPH. AUREUS | TRUSTEES OF BOSTON UNIVERSITY | 2001-02-06 | — | — | US | disclosed |
| EP-1043990-A1 | PYRONIN ANTIBACTERIALS, PROCESS AND NOVEL INTERMEDIATES THERETO | Scriptgen Pharmaceuticals, Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| US-6127551-A | 4-HYDROXY-6-ETHYOXYCARBONYLALKENYL-2H-PYRAN-2-ONE IS ACYLATED WITH PROPIONYL CHLORIDE TO FORM A KETONE ADDUCT, FOLLOWED BY BASE-CATALYZED ALDOL TO FROM A PYRONE ALDOL; MESYLATION, FORM A PYRONE KETONE; AND CURTIUS SEQUENCE TO FORM MYXOPYRONIN | SCRIPTGEN PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| US-6090953-A | PREPARING A MYXOPYRONIN | SCRIPTGEN PHARMACEUTICALS, INC. (US) | 2000-07-18 | — | — | US | disclosed |
| US-6022983-A | PREPARING A MYXOPYRONIN | SCRIPTGEN PHARMACEUTICALS, INC. (US) | 2000-02-08 | — | — | US | disclosed |
| US-5986111-A | CONDENSATION OF ALDEHYDE WITH PYRONE TO FORM ADDUCT, OXIDATION AND SAPONIFICATION | SCRIPTGEN PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1999034793-A1 | PYRONIN ANTIBACTERIALS, PROCESS AND NOVEL INTERMEDIATES THERETO | SCRIPTGEN PHARMACEUTICALS, INC. (US) | 1999-07-15 | — | — | WO | disclosed |
| EP-0892774-A2 | PYRONIN ANTIBACTERIALS, PROCESS AND NOVEL INTERMEDIATES THERETO | SCRIPTGEN PHARMACEUTICALS, INC. (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997034569-A2 | PYRONIN ANTIBACTERIALS, PROCESS AND INTERMEDIATES | SCRIPTGEN PHARMACEUTICALS, INC. (US) | 1997-09-25 | — | — | WO | disclosed |